Rudolf W.
- Country
- Germany
- Department
- Medical Oncology
Research Overview
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Phase II Open‑Label Multicenter Study of Subcutaneous Epcoritamab in Relapsed/Refractory Marginal Zone Lymphoma (EPOS‑1)
Data & Insights
Has run more than one trial at 498 of 889 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in various subtypes of breast cancer treatment, with particular focus on HER2-positive, HER2-negative, and triple-negative breast cancer.
- Early-stage and advanced breast cancer management
- Hormone receptor-positive disease treatments
- Neoadjuvant therapy approaches
Primary interest in targeted therapies including CDK4/6 inhibitors and novel therapeutic combinations.
Hematologic Malignancies
Focuses on treating various blood cancers including multiple myeloma, lymphomas, and myelodysplastic syndrome.
- Diffuse large B-cell lymphoma treatments
- Marginal zone lymphoma therapy
- Hodgkin lymphoma management
Expertise in novel immunotherapy approaches and combination treatment strategies.
Precision Medicine
Specializes in biomarker-driven treatment approaches and personalized therapy strategies.
- PIK3CA mutation-targeted therapies
- ESR1 mutation treatments
- BRCA mutation-related interventions
Focus on developing targeted therapeutic approaches based on molecular profiling.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.